US Semiconductor & Biomedical Device Startups

How This List Was Built

This article focuses on U.S.-based companies in semiconductors and biomedical or medical-device technology that announced Series B or Series C financing from February 2025 through 2026.

A second filter is company size. The objective is to focus on teams reported or estimated at fewer than 200 employees. This makes the list more useful for research into companies that may still have relatively lean operating structures while managing increasingly complex technical, manufacturing, clinical or commercial workflows.

Employee counts are inherently time-sensitive. Private-company headcount data can also differ between databases. Accordingly, the employee figures below should be treated as screening information, not permanent company facts.

Funding information was cross-checked against company announcements and reputable financial, venture and industry sources where available.

Why Recently Funded, Small Technical Teams Matter

Semiconductor and medical-device startups can have unusually demanding operating environments.

A semiconductor company may be coordinating chip design, verification, fabrication partners, packaging, testing, supply-chain relationships and customer engineering.

A medical-device company may simultaneously manage product development, quality systems, clinical programs, regulatory documentation, manufacturing partners and commercial preparation.

These requirements can create a gap between the complexity of the business and the size of the internal team.

That gap does not automatically mean a startup needs custom automation. It does, however, create sensible areas for research: repetitive workflows, structured data collection, document routing, reporting, operational alerts and integrations between systems.

The interesting signal is not simply that a startup raised money. It is what the new capital allows the company to attempt with the team it has.

Semiconductor Startups

The semiconductor group below spans sensing, lithography, semiconductor services and AI computing. The companies operate at different points in the semiconductor value chain, which is important when considering their operating needs.

These companies illustrate different forms of semiconductor complexity. Lumotive is associated with optical sensing and semiconductor components; xLight is addressing a critical part of chip manufacturing; GSME is building a semiconductor services platform; and Positron and MatX are pursuing specialized AI-compute architectures.

Biomedical and Medical-Device Startups

The medical-device group presents a different operating profile. Clinical development, regulatory work, quality systems, manufacturing readiness and hospital-facing workflows can all create substantial operational complexity.

The medical-device examples show why funding should be interpreted alongside development stage. A Series B or C round can coincide with clinical-trial execution, regulatory submissions, manufacturing preparation or commercialization rather than simply conventional corporate expansion.

Where Custom Automation May Be Worth Evaluating

The purpose of identifying these companies is not to assume that every recently funded startup needs automation.

A better approach is to identify workflows where repetitive work, fragmented information or cross-functional coordination could justify a custom solution.

These are examples of areas worth investigating, not claims about any individual company's internal processes.

For a small technical company, the strongest automation opportunity is often not a large enterprise software replacement. It can be a narrowly defined workflow that removes repeated manual work while preserving human review where judgement, compliance or technical expertise is required.

What a Series B or C Round Can Signal

A funding round does not tell an investor everything about a company's prospects. It does, however, provide a useful event around which additional research can be organized.

Product maturity

At Series B or C, many technical companies are attempting to move beyond early technical validation toward larger-scale development, validation or commercialization. The exact stage differs considerably by industry.

Operational complexity

New capital can increase the number of suppliers, clinical sites, customers, manufacturing partners, technical projects or regulatory activities a startup manages.

Hiring versus infrastructure

A startup does not necessarily respond to funding by hiring hundreds of employees. Some capital may instead be deployed toward equipment, manufacturing, clinical studies, infrastructure, inventory, specialized contractors or strategic partnerships.

A new research window

For investors and market researchers, a recent funding event creates a natural point for examining the company again.

Questions worth asking include:

• What was the stated purpose of the financing?
• Which investors participated?
• What stage is the company's product or platform at?
• Is the company entering a more operationally complex phase?
• What new customers, markets or geographies are being targeted?
• Has the team grown materially since the round?
• Which external partners are becoming important?

The Investor Intelligence Perspective

From an investment-intelligence perspective, the most useful part of this dataset is not simply the list of company names.

Each company can be connected to a broader network:

Company → Funding Round → Investors → Technology → Sector → Geography → Operating Signals

That relationship can help researchers move from a funding announcement toward a deeper understanding of capital allocation.

For example, an investor researching semiconductor capital could compare which funds repeatedly back chip companies, which technical categories attract financing and how individual investors' portfolios overlap.

A medical-device researcher could similarly examine investors participating in cardiovascular, oncology or neurological-device companies and then investigate related portfolio activity.

This is where funding intelligence becomes more valuable than a simple news headline.

The round is the starting point. The surrounding relationships provide the context.

How InveLedger Fits Into This Research

InveLedger is focused on investment intelligence across companies, investors, funding rounds, portfolios, sectors and broader capital movements.

A research question such as "which U.S. semiconductor startups raised Series B or Series C funding while maintaining relatively small teams?" is more useful when it can lead to additional questions.

• Who invested in these companies?
• Which investors appear repeatedly?
• Which sectors are attracting the capital?
• Which companies sit in the same investor portfolios?
• How has the funding history developed?
• What other companies are connected to the same investment themes?

Those questions are part of the broader investment intelligence problem: turning individual records into connected context.

Readers interested in the broader concept can also explore InveLedger's guide to investment intelligence and its discussion of venture capital as part of the private-market ecosystem.

The objective is not to tell investors which companies to back. It is to make the surrounding investment information easier to research and understand.

What to Watch Next

The companies in this research set sit at the intersection of large technical ambitions and relatively compact teams.

In semiconductors, that can mean moving from chip architecture or specialized components toward manufacturing, customer deployment and larger production relationships.

In medical devices, it can mean moving from product development toward pivotal studies, regulatory milestones, manufacturing readiness and eventual commercialization.

Those transitions can produce new information signals that investors and operators should monitor.

The most useful next step is not simply to create a larger list.

It is to connect each company with its investors, financing history, technology category, competitors, partners and operational milestones.

Frequently Asked Questions